PMID- 18555813
OWN - NLM
STAT- MEDLINE
DCOM- 20080922
LR  - 20131121
IS  - 0010-7824 (Print)
IS  - 0010-7824 (Linking)
VI  - 78
IP  - 1
DP  - 2008 Jul
TI  - Suppression of ovarian activity with a drospirenone-containing oral contraceptive 
      in a 24/4 regimen.
PG  - 16-25
LID - 10.1016/j.contraception.2008.02.019 [doi]
AB  - BACKGROUND: This study was conducted to compare ovarian activity of an oral 
      contraceptive containing drospirenone (drsp) 3 mg plus ethinylestradiol (EE) 20 
      mcg administered in 24/4 regimen compared with the conventional 21/7 regimen, 
      during intended use and following predefined dosing errors. STUDY DESIGN: Women 
      aged 18-35 years who ovulated or had a follicular diameter of >or=15 mm on or 
      before Day 23 during a pretreatment cycle were admitted into this double-blind, 
      randomized study. Participants underwent 3 treatment cycles with drsp 3 mg/EE 20 
      mcg in a 24/4 (n=52) or a 21/7 (n=52) regimen. In the third treatment cycle, the 
      initial three pills in both groups were replaced with placebos. Ovarian activity 
      was classified using the Hoogland scale during pretreatment and during Cycles 2 
      and 3. RESULTS: Suppression of ovarian activity was more pronounced with the 24/4 
      regimen--the odds ratio for a lower Hoogland score (i.e., greater ovarian 
      suppression) with the 24/4 regimen compared with the conventional 21/7 regimen 
      were 6.01 (95% CI: 2.29-17.94) and 3.06 (95% CI: 1.44-6.65) for Cycles 2 and 3, 
      respectively. More women in the 24/4 regimen group had no ovarian activity 87.8% 
      vs. 56.0% during Cycle 2 and 55.1% vs. 30.0% during Cycle 3. The 24/4 regimen was 
      associated with a more consistent suppression (less fluctuation) of endogenous 
      estradiol. CONCLUSION: The drsp 3 mg/EE 20 mcg oral contraceptive in a 24/4 
      regimen was associated with greater ovarian suppression (despite intentional 
      dosing error), which results in decreased hormonal fluctuations, and may increase 
      contraceptive efficacy with the low-dose formulation.
FAU - Klipping, Christine
AU  - Klipping C
AD  - Dinox BV, 9713 GZ Groningen, The Netherlands.
FAU - Duijkers, Ingrid
AU  - Duijkers I
FAU - Trummer, Dietmar
AU  - Trummer D
FAU - Marr, Joachim
AU  - Marr J
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080527
PL  - United States
TA  - Contraception
JT  - Contraception
JID - 0234361
RN  - 0 (Androstenes)
RN  - 0 (Contraceptives, Oral, Combined)
RN  - 423D2T571U (Ethinyl Estradiol)
RN  - 4TI98Z838E (Estradiol)
RN  - N295J34A25 (drospirenone)
SB  - IM
EIN - Contraception. 2008 Oct;78(4):350
MH  - Adolescent
MH  - Adult
MH  - Androstenes/*pharmacology
MH  - Confidence Intervals
MH  - *Contraceptives, Oral, Combined
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Estradiol/*blood/metabolism
MH  - Ethinyl Estradiol/*pharmacology
MH  - Female
MH  - Humans
MH  - Odds Ratio
MH  - Ovary/*drug effects/physiology
MH  - Treatment Outcome
EDAT- 2008/06/17 09:00
MHDA- 2008/09/23 09:00
CRDT- 2008/06/17 09:00
PHST- 2007/04/27 00:00 [received]
PHST- 2008/02/21 00:00 [revised]
PHST- 2008/02/22 00:00 [accepted]
PHST- 2008/06/17 09:00 [pubmed]
PHST- 2008/09/23 09:00 [medline]
PHST- 2008/06/17 09:00 [entrez]
AID - S0010-7824(08)00110-8 [pii]
AID - 10.1016/j.contraception.2008.02.019 [doi]
PST - ppublish
SO  - Contraception. 2008 Jul;78(1):16-25. doi: 10.1016/j.contraception.2008.02.019. 
      Epub 2008 May 27.